Pharmaceuticals - Stirling, Scotland, United Kingdom
The CNS Company (TCNSC) is the ONLY CRO that is exclusively focused on conducting clinical trials in CNS diseases. We team have over 15 years of experience in this challenging area covering diseases as diverse as Alzheimer's disease, Traumatic Brain Injury and schizophrenia, and orphan diseases such as Huntington's disease and frontotemporal dementia. We offer the full service and work globally. With its subjective assessments and often subjective diagnosis, along with lack of biomarkers and high placebo response, CNS is like no other therapeutic area. TCNSC have a wealth of experience in CNS clinical trial design, understand the strengths and weaknesses of a multitude of subjective and objective assessments used in CNS studies, and have excellent, long term relationships with neurologists and psychiatrists enabling outstanding recruitment. TCNSC personnel are also experienced in attending meetings with FDA and EMA, negotiating Special Protocol Assessment with the FDA and obtaining Scientific Advice with the EMA on specific projects within the CNS arena.The staff at TCNSC are the world's first CRO team to deliver 437 patients in less than 12 months for a phase III clinical trial in a CNS orphan indication.